

11 April 2008

Company Announcement Shareholder Update

More Antibiotics have been identified

Recent screening results of approximately 300 field isolates have indicated that nine have significant antibiotic activity against the company's type target Methicillin Resistant Staphylococcus Aureus (MRSA) as well as a further panel of ten MRSA of various antibiotic resistant patterns. DNA sequencing so far suggests three of the nine isolates cannot be typed further than to genus level. A second level screening of the antibiotic activity of these isolates is now in progress.

Discovery of Enzyme used to Produce Glucosamine

Recent results from actinomycetes found in a new niche area of the West Australian environment has yielded five actinomycetes and a small number of other soil bacteria with significant chitinase activity. Chitinase is an enzyme used commercially to produce glucosamine which is commonly used in the control of joint pains and inflammatory reactions in humans. The commercial possibilities of the find are being investigated.

Healing Solution & Organic Buffering Delivery System

Due to international patent complications the company will not proceed with the purchase of the healing solution and buffering delivery system.

On behalf of the Board of Directors
Actinogen Limited

